PriceTargets.com logo

Doximity - DOCS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $51.07
  • Forecasted Upside: 3.37%
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$49.40 As of 11/15/2024 01:00 AM ET
▼ -2.64 (-5.07%)

This chart shows the closing price for DOCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Doximity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOCS

Analyst Price Target is $51.07
▲ +3.37% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $51.07, with a high forecast of $75.00 and a low forecast of $30.00. The average price target represents a 3.37% upside from the last price of $49.40.

This chart shows the closing price for DOCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 18 contributing investment analysts is to hold stock in Doximity. This rating has held steady since July 2023, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 3 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 1 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
8/18/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
10/17/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024The Goldman Sachs GroupInitiated CoverageNeutral$58.00
11/14/2024Truist FinancialBoost TargetHold ➝ Hold$35.00 ➝ $49.00
11/14/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$33.00 ➝ $53.00
11/13/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$40.00 ➝ $60.00
11/13/2024Canaccord Genuity GroupDowngradeBuy ➝ Hold$40.00 ➝ $60.00
11/11/2024BarclaysBoost TargetOverweight ➝ Overweight$52.00 ➝ $75.00
11/8/2024Raymond JamesReiterated RatingOutperform ➝ Outperform$37.00 ➝ $65.00
11/8/2024KeyCorpUpgradeSector Weight ➝ Overweight$70.00
11/8/2024Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$19.00 ➝ $41.00
10/30/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$26.00 ➝ $33.00
10/15/2024BarclaysUpgradeEqual Weight ➝ Overweight$35.00 ➝ $52.00
10/8/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$34.00 ➝ $45.00
10/7/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$32.00 ➝ $45.00
9/17/2024Baird R WUpgradeStrong-Buy
9/17/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$41.00 ➝ $45.00
8/20/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$37.00 ➝ $40.00
8/19/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$27.00 ➝ $30.00
8/14/2024Truist FinancialReiterated RatingHold ➝ Hold$31.00 ➝ $35.00
8/9/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$29.00 ➝ $34.00
8/9/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$29.00 ➝ $32.00
8/9/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$31.00 ➝ $35.00
8/9/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$25.00 ➝ $26.00
8/9/2024Needham & Company LLCUpgradeHold ➝ Buy$38.00
7/18/2024Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$27.00 ➝ $19.00
5/17/2024William BlairReiterated RatingOutperform
5/17/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$28.00 ➝ $29.00
5/17/2024Needham & Company LLCReiterated RatingHold
4/25/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$25.00
4/23/2024Morgan StanleyReiterated RatingUnderweight ➝ Underweight$25.00 ➝ $25.00
4/2/2024Evercore ISIReiterated RatingIn-Line ➝ In-Line$30.00
3/15/2024JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight$22.00 ➝ $25.00
2/26/2024Leerink PartnrsReiterated RatingMarket Perform
2/26/2024Leerink PartnersInitiated CoverageMarket Perform$32.00
2/9/2024Truist FinancialBoost TargetHold ➝ Hold$28.00 ➝ $29.00
2/9/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$25.00 ➝ $27.00
1/23/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$29.00 ➝ $32.00
1/3/2024BarclaysInitiated CoverageEqual Weight$31.00
1/2/2024Bank of AmericaUpgradeUnderperform ➝ Neutral$21.00 ➝ $29.00
11/10/2023Piper SandlerBoost TargetNeutral ➝ Neutral$21.00 ➝ $23.00
11/10/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$21.00 ➝ $25.00
10/11/2023Evercore ISILower Target$24.00 ➝ $21.00
9/5/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$40.00 ➝ $33.00
8/10/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$37.00 ➝ $25.00
8/9/2023Raymond JamesLower TargetOutperform ➝ Outperform$40.00 ➝ $30.00
8/9/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$28.00 ➝ $21.00
8/9/2023Truist FinancialLower TargetHold ➝ Hold$33.00 ➝ $28.00
8/9/2023Bank of AmericaLower Target$28.00 ➝ $24.00
8/9/2023Piper SandlerLower Target$36.00 ➝ $27.00
8/9/2023Needham & Company LLCDowngradeBuy ➝ Hold
8/9/2023GuggenheimDowngradeBuy ➝ Neutral
8/3/2023Piper SandlerDowngradeOverweight ➝ Neutral$38.00 ➝ $36.00
6/5/2023Truist FinancialLower Target$36.00 ➝ $33.00
5/17/2023Evercore ISILower Target$33.00 ➝ $32.00
5/1/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$39.00 ➝ $37.00
2/17/2023JPMorgan Chase & Co.Lower TargetUnderweight$60.00 ➝ $30.00
2/10/2023Piper SandlerBoost Target$35.00 ➝ $38.00
2/10/2023Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $39.00
2/10/2023Canaccord Genuity GroupLower TargetBuy$42.00 ➝ $41.00
2/10/2023Needham & Company LLCReiterated RatingBuy$45.00
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$32.00 ➝ $29.00
11/11/2022Evercore ISIBoost Target$28.00 ➝ $32.00
11/11/2022Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $44.00
11/11/2022Piper SandlerLower Target$39.00 ➝ $35.00
10/31/2022Wells Fargo & CompanyInitiated CoverageOverweight$38.00
10/23/2022Evercore ISIInitiated CoverageInline$28.00
10/13/2022BTIG ResearchInitiated CoverageNeutral
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
9/7/2022Truist FinancialInitiated CoverageHold$35.00
8/8/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$47.00 ➝ $42.00
8/5/2022Canaccord Genuity GroupLower TargetBuy$47.00 ➝ $42.00
8/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform$43.00 ➝ $29.00
8/5/2022Piper SandlerLower Target$44.00 ➝ $39.00
7/29/2022Berenberg BankReiterated RatingInitiates
7/28/2022Berenberg BankInitiated CoverageBuy$49.00
5/18/2022Piper SandlerLower Target$81.00 ➝ $44.00
5/18/2022Canaccord Genuity GroupLower Target$65.00 ➝ $44.00
5/18/2022Jefferies Financial GroupLower TargetBuy$78.00 ➝ $46.00
5/18/2022Bank of AmericaLower TargetNeutral$55.00 ➝ $36.00
5/18/2022GuggenheimLower TargetBuy$70.00 ➝ $52.00
5/18/2022Needham & Company LLCLower TargetBuy$70.00 ➝ $45.00
5/18/2022The Goldman Sachs GroupLower TargetBuy$72.00 ➝ $56.00
5/18/2022Morgan StanleyLower TargetEqual Weight$55.00 ➝ $35.00
5/18/2022Raymond JamesLower Target$60.00 ➝ $40.00
5/18/2022Robert W. BairdLower Target$68.00 ➝ $45.00
4/6/2022GuggenheimInitiated CoverageBuy$70.00
4/4/2022Bank of AmericaInitiated CoverageNeutral$55.00
3/23/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $55.00
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00
2/9/2022Needham & Company LLCLower TargetBuy$90.00 ➝ $70.00
2/9/2022Raymond JamesLower TargetOutperform$80.00 ➝ $60.00
12/17/2021Morgan StanleyLower TargetEqual Weight$72.00 ➝ $58.00
12/14/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$70.00 ➝ $60.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$78.00
11/16/2021Robert W. BairdInitiated CoverageOutperform$84.00
11/10/2021The Goldman Sachs GroupBoost TargetNeutral$40.00 ➝ $45.00
11/10/2021Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $72.00
11/10/2021Raymond JamesBoost TargetOutperform$62.00 ➝ $80.00
11/10/2021Leerink PartnersBoost TargetOutperform$65.00 ➝ $72.00
11/10/2021Needham & Company LLCBoost TargetBuy$62.00 ➝ $90.00
11/10/2021Piper SandlerBoost TargetOverweight$68.00 ➝ $81.00
8/31/2021Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $71.00
8/26/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00
8/11/2021Raymond JamesBoost TargetOutperform$60.00 ➝ $62.00
7/19/2021Needham & Company LLCInitiated CoverageBuy$62.00
7/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$60.00
7/19/2021Raymond JamesInitiated CoverageOutperform$60.00
7/19/2021Morgan StanleyInitiated CoverageEqual Weight$52.00
7/19/2021William BlairInitiated CoverageOutperform
7/19/2021Leerink PartnersInitiated CoverageOutperform$65.00
7/19/2021The Goldman Sachs GroupInitiated CoverageNeutral
7/19/2021Piper SandlerInitiated CoverageOverweight$68.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 25 very positive mentions
  • 55 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 13 very positive mentions
  • 55 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 20 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 15 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 18 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 23 very positive mentions
  • 42 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 23 very positive mentions
  • 42 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Doximity logo
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $49.40
Low: $48.16
High: $50.81

50 Day Range

MA: $43.40
Low: $36.54
High: $61.25

52 Week Range

Now: $49.40
Low: $22.96
High: $61.75

Volume

3,180,866 shs

Average Volume

2,068,474 shs

Market Capitalization

$9.22 billion

P/E Ratio

56.78

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Doximity?

The following sell-side analysts have issued reports on Doximity in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Evercore ISI, JPMorgan Chase & Co., KeyCorp, Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, The Goldman Sachs Group, Inc., Truist Financial Co., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for DOCS.

What is the current price target for Doximity?

0 Wall Street analysts have set twelve-month price targets for Doximity in the last year. Their average twelve-month price target is $51.07, suggesting a possible upside of 3.4%. Barclays PLC has the highest price target set, predicting DOCS will reach $75.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $30.00 for Doximity in the next year.
View the latest price targets for DOCS.

What is the current consensus analyst rating for Doximity?

Doximity currently has 11 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DOCS, but not buy more shares or sell existing shares.
View the latest ratings for DOCS.

What other companies compete with Doximity?

Other companies that are similar to Doximity include RealPage, Amdocs, Avalara, Smartsheet and Pegasystems. Learn More about companies similar to Doximity.

How do I contact Doximity's investor relations team?

The company's listed phone number is 650-549-4330 and its investor relations email address is [email protected]. The official website for Doximity is www.doximity.com. Learn More about contacing Doximity investor relations.